A scoping review of the measurement and analysis of frailty in randomised controlled trials
Scoping Review zur Messung und Analyse von Frailty in randomisierten kontrollierten Studien
Age and Ageing · 01.11.2024 · 53 (11)
DOI: 10.1093/ageing/afae258 ↗Auf einen Blick
Die Übersicht zeigt eine hohe Variabilität der Frailty-Messung in 415 RCTs. Am häufigsten wurden das Frailty-Phänotyp-Modell und der Frailty-Index verwendet.
Fragestellung
Wie wird Frailty in randomisierten kontrollierten Studien quantifiziert, in welchem Kontext und zu welchem Zweck wird sie erfasst?
Methode
Scoping Review von RCTs; Suche in fünf elektronischen Datenbanken; Extraktion von Interventionstyp, Frailty-Messung und Zweck der Frailty-Erfassung.
Ergebnisse
415 RCTs. Frailty diente zur Definition der Zielpopulation (166), als Outcome (156), als Effektmodifikator (61), als rein deskriptive Variable (42) oder als prognostischer Marker (78). Es wurden 28 Frailty-Messungen plus 29 studienspezifische Messungen genutzt.
Schlussfolgerung der Autor:innen
Die Frailty-Messung in RCTs ist stark variabel. Die Autor:innen betonen, dass das Verständnis der Eigenschaften der verwendeten Frailty-Messungen Priorität hat, damit Studienergebnisse die Versorgung von Menschen mit Frailty informieren können.
Kernaussagen
- 415 RCTs untersuchten Frailty in verschiedenen Interventionskontexten
- 28 Frailty-Messungen plus 29 studienspezifische Messungen wurden genutzt
- Frailty-Phänotyp-Modell und Frailty-Index waren am häufigsten
Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.
Kurz gefasst
Scoping Review in der Zeitschrift Age and Ageing, online erschienen am 21.11.2024. Verfasst von Yanhe Sun und 6 weiteren Autor:innen. Beteiligte Einrichtung: School of Health and Wellbeing, University of Glasgow, Glasgow, UK. Hauptthemen laut MEDLINE: Randomized Controlled Trials as Topic, Frailty, Geriatric Assessment, Frail Elderly. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Gerontologische Pflege
Abstract (Originalsprache)
Background
Frailty is of increasing interest in trials, either as a target of intervention, as an outcome or as a potential treatment modifier. However, frailty measurement is often highly variable. This scoping review assessed how frailty is quantified in randomised controlled trials (RCTs), in what context and for what purposes.
Methods
We searched five electronic databases for RCTs in which frailty was measured among trial participants. We extracted data on intervention type, the frailty measure used and the purpose for which frailty was assessed. We then compared these data according to reasons for frailty assessment.
Results
We identified 415 RCTs assessing frailty across a range of interventions. Frailty was used to define the target population (166 trials), as an outcome (156 trials), as an effect modifier examining interaction of frailty on treatment effect (61 trials), as a purely descriptive characteristic (42 trials) or as a prognostic marker examining the impact of frailty on future health outcome (78 trials). The trials used 28 different measures of frailty (plus 29 additional trial-specific measures). The frailty phenotype model was the most common overall (164 trials), for defining the target population (90/166 trials) and as an outcome (81/156 trials). The cumulative deficit model frailty index was also frequently used (102 trials) and was most common among trials assessing treatment effect modification (21/61 trials).
Conclusion
Frailty measurement in RCTs is highly variable. Understanding the properties of respective frailty measures and how these relate to frailty as encountered in clinical practice is a priority to ensure that trial findings can inform healthcare delivery for people living with frailty.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- School of Health and Wellbeing, University of Glasgow, Glasgow, UK.
- AGE Research Group, Translational and Clinical Research Institute, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, UK.
- NIHR Newcastle Biomedical Research Centre, Newcastle upon Tyne NHS Foundation Trust, Cumbria Northumberland Tyne and Wear NHS Foundation Trust and Newcastle University, Newcastle upon Tyne, UK.
- Academic Unit for Ageing & Stroke Research, University of Leeds, Bradford Teaching Hospitals NHS Foundation Trust, Bradford, UK.
- MRC/CSO Social and Public Health Sciences Unit, University of Glasgow, Glasgow, UK.
- Robertson Centre for Biostatistics, University of Glasgow, Glasgow, UK.
ORCID-Profile: Peter Hanlon
Zitieren
APA
Sun, Y., Witham, M. D., Clegg, A., Taylor, R. S., Dibben, G., McAllister, D., & Hanlon, P. (2024). A scoping review of the measurement and analysis of frailty in randomised controlled trials. Age and Ageing, 53(11). https://doi.org/10.1093/ageing/afae258
Vancouver
Sun Y, Witham MD, Clegg A, Taylor RS, Dibben G, McAllister D, et al. A scoping review of the measurement and analysis of frailty in randomised controlled trials. Age and Ageing. 2024;53(11). doi:10.1093/ageing/afae258
BibTeX
@article{Sun2024,
author = {Sun, Yanhe and Witham, Miles D and Clegg, Andy and Taylor, Rod S and Dibben, Grace and McAllister, David and Hanlon, Peter},
title = {A scoping review of the measurement and analysis of frailty in randomised controlled trials},
journal = {Age and Ageing},
year = {2024},
volume = {53},
number = {11},
doi = {10.1093/ageing/afae258}
}
EUVIMED